Scarica l'app Stockscreener
441.36
0.56%
2.44
Dopo l'orario di chiusura:
441.20
-0.16
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$438.92
Aprire:
$440.46
Volume 24 ore:
2.04M
Relative Volume:
1.49
Capitalizzazione di mercato:
$111.98B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
31.11
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
-4.85%
1M Prestazione:
-2.99%
6M Prestazione:
-6.00%
1 anno Prestazione:
+5.85%
Intervallo 1D:
$437.46
$445.77
Intervallo di 1 settimana:
$436.69
$464.59
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
The Truth About Vertex Pharmaceuticals (VRTX): Biotech Beast Or Overhyped Bubble? - AD HOC NEWS
12 Best Future Stocks to Buy For the Long Term - Insider Monkey
The Truth About Vertex Pharma: Why Wall Street Can’t Stop Watching This Biotech Beast - AD HOC NEWS
Vertex Pharma Is Quietly Dominating – Is This Biotech Stock the Next Monster Win? - AD HOC NEWS
Growth Report: Can Vertex Pharmaceuticals Incorporated reach all time highs this year - baoquankhu1.vn
Implied Volatility Surging for Vertex Pharmaceuticals Stock Options - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Private Client Wealth LLC - MarketBeat
Country Trust Bank Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here's what to expect from Vertex Pharmaceuticals' next earnings report - MSN
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% - The Motley Fool
Meritage Portfolio Management Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Finviz
Manning & Napier Advisors LLC Purchases 241,242 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Nordea Investment Management AB - MarketBeat
What is Vertex Pharmaceuticals Incorporated s debt to equity ratio2025 Key Highlights & Risk Adjusted Swing Trade Ideas - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Vertex Pharmaceuticals Targets Five Product Launches in Five Years Across Diverse Disease Areas - geneonline.com
JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease - Pharmaceutical Technology
Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report - Yahoo Finance
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate - Chartmill
Sumitomo Mitsui Trust Group Inc. Acquires 45,623 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX: Strong growth in CF, pain, and renal, with five launches in five years and $12B revenue guidance - TradingView — Track All Markets
Bernstein Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
How Is The Market Feeling About Vertex Pharmaceuticals Inc? - Benzinga
Bernstein upgrades Vertex ahead of key renal trial readouts By Investing.com - Investing.com India
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - BioPharma Dive
Vertex Pharma Is Quietly Exploding – Here’s What Wall Street Isn’t Telling You - AD HOC NEWS
Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4 - Insider Monkey
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Hardman Johnston Global Advisors LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Horizon Corp Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Citizens Financial Group Inc. RI Acquires 9,963 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor MeetingsJanuary 11, 2026 - BioSpace
Vertex Pharmaceuticals Incorporated : Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - marketscreener.com
New York State Teachers Retirement System Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Best Stocks to Invest $50,000 in Right Now - Finviz
Spire Wealth Management Sells 8,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Parnassus Investments LLC Lowers Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sumitomo Mitsui DS Asset Management Company Ltd Has $21.54 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nisa Investment Advisors LLC Has $21.85 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Oregon Public Employees Retirement Fund Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
What dividend safety score for Vertex Pharmaceuticals Incorporated stockGlobal Markets & Weekly High Conviction Ideas - ulpravda.ru
How The Vertex Pharmaceuticals (VRTX) Story Is Shifting With New Analyst Targets And CF Outlook - Yahoo Finance
Insider Sell: Ourania Tatsis Sells 4,500 Shares of Vertex Pharma - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Ourania Tatsis Sells 4,500 Shares - MarketBeat
Vertex Pharmaceuticals Officer Sells 4,500 Shares - TradingView — Track All Markets
Does Vertex Pharmaceuticals (VRTX) Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.20%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):